CardioFocus Illuminates Underserved “AF-Alone” Market With Light Ring
This article was originally published in The Gray Sheet
Executive Summary
CardioFocus expects its Light Ring catheter to be among the first devices to cure drug-resistant paroxysmal atrial fibrillation (AF) in patients not indicated for surgery
You may also be interested in...
Cardima Revelation Tx Trial Results Show 45% Cure Rate For AF Episodes
Cardima is hoping that clinical data showing 85% of patients had a reduction in their AF episodes of greater than or equal to 50% after being treated with its Revelation Tx system will prompt FDA's Circulatory System Devices Panel to recommend approval
Cardima Revelation Tx Trial Results Show 45% Cure Rate For AF Episodes
Cardima is hoping that clinical data showing 85% of patients had a reduction in their AF episodes of greater than or equal to 50% after being treated with its Revelation Tx system will prompt FDA's Circulatory System Devices Panel to recommend approval
Edwards BioPhysio Valve To Solve Stentless Versus Stented Conundrum
Edwards Lifesciences will begin clinical trials this year for its BioPhysio replacement heart valve technology, combining the advantages of the company's stented and stentless tissue replacement valves